Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 207,097 | 182,824 | 229,356 | 194,606 | 210,171 |
| Receivables | 734,482 | 767,569 | 756,629 | 720,915 | 754,207 |
| Inventories | 302,550 | 279,550 | 290,156 | 278,544 | 336,200 |
| Other current assets | 166,440 | 129,921 | 100,230 | 105,796 | 101,514 |
| TOTAL | $1,532,104 | $1,469,862 | $1,506,358 | $1,403,071 | $1,494,723 |
| Non-Current Assets | |||||
| PPE Net | 1,591,625 | 1,606,733 | 1,587,069 | 1,604,014 | 1,639,978 |
| Investments And Advances | 194,635 | 216,073 | 214,026 | 218,350 | 235,987 |
| Intangibles | 3,493,375 | 3,538,717 | 3,529,107 | 3,570,008 | 3,903,053 |
| Other Non-Current Assets | 702,073 | 729,160 | 745,806 | 732,902 | 730,101 |
| TOTAL | $5,981,708 | $6,090,683 | $6,076,008 | $6,125,274 | $6,509,119 |
| Total Assets | $7,513,812 | $7,560,545 | $7,582,366 | $7,528,345 | $8,003,842 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 169,615 | 145,798 | 149,334 | 140,337 | 135,963 |
| Accrued Expenses | 498,592 | 459,076 | 439,792 | 411,428 | 419,201 |
| Other current liabilities | 215,953 | 207,224 | 211,467 | 194,014 | 205,089 |
| TOTAL | $1,121,888 | $1,080,438 | $1,051,055 | $994,101 | $1,012,221 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,185,453 | 2,332,374 | 2,510,754 | 2,240,205 | 2,326,653 |
| Deferred Revenues | 237,728 | 268,340 | 250,462 | 248,322 | 251,968 |
| Other Non-Current Liabilities | 672,005 | 678,463 | 712,761 | 720,059 | 709,078 |
| TOTAL | $2,981,599 | $3,120,477 | $3,331,192 | $3,067,292 | $3,204,494 |
| Total Liabilities | $4,103,487 | $4,200,915 | $4,382,247 | $4,061,393 | $4,216,715 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 49,215 | 49,214 | 49,116 | 51,142 | 51,136 |
| Common Shares | 514 | 513 | 512 | 511 | 517 |
| Retained earnings | 1,944,317 | 1,889,895 | 1,837,569 | 1,812,100 | 2,122,835 |
| Other shareholders' equity | -187,171 | -160,496 | -259,014 | -311,896 | -187,638 |
| TOTAL | $3,410,325 | $3,359,630 | $3,200,119 | $3,466,952 | $3,787,127 |
| Total Liabilities And Equity | $7,513,812 | $7,560,545 | $7,582,366 | $7,528,345 | $8,003,842 |